The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - IMPaRT.ai
Consulting or Advisory Role - Acrotech Biopharma; Crispr Therapeutics; Pfizer/Seagen; Salarius Pharmaceuticals; Secura Bio; Yingli Pharma
Research Funding - Acrotech Biopharma; AstraZeneca; Crispr Therapeutics; Innate Pharma; Legend Biotech; Merck; Ono Pharmaceutical; Pfizer/Seagen; Trillium Therapeutics; Yingli Pharma
Other Relationship - IMPaRT.ai
A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL).
 
Swaminathan Iyer
No Relationships to Disclose
 
Steven Horwitz
Honoraria - seagen
Consulting or Advisory Role - Abcuro; Arvinas; Autolus Therapeutics; Auxilius Pharma; Corvus Pharmaceuticals; DAAN Biotherapeutics; Daiichi Sankyo; J&J Medicine/Janssen Research & Development; Kyowa Hakko Kirin; MarchBIO; Ono Pharmaceutical; Pfizer; Secura Bio; Shoreline Biosciences; SymBio Pharmaceuticals; Takeda
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Celgene (Inst); crispr therapeutics (Inst); Daiichi Sankyo (Inst); Kyowa Kirin International (Inst); Seagen (Inst); Secura Bio (Inst); Takeda (Inst); Trillium Therapeutics (Inst)
Travel, Accommodations, Expenses - SeaGen; Takeda
 
Salvia Jain
Consulting or Advisory Role - Abcuro; Acrotech Biopharma; Daiichi Sankyo; Myeloid Therapeutics; SIRPant Immunotherapeutics
 
Julie Vose
Honoraria - Abbvie; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; Genmab; Ono Pharmaceutical
Consulting or Advisory Role - Foresight Diagnostics; Novartis
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Epizyme; Genmab; Kite, a Gilead company (Inst); Loxo; Novartis (Inst); Seagen (Inst)
 
Aleksandr Lazaryan
Consulting or Advisory Role - Sanofi
 
Aaron Goodman
No Relationships to Disclose
 
Michael Tees
Research Funding - 2seventy (Inst); Accutar Biotech (Inst); Allogene Therapeutics (Inst); Cargo (Inst); Juno Therapeutics (Inst); Kite Therapeutics (Inst); Merck (Inst); Nkarta (Inst); Step Pharma (Inst)
 
Anne Beavan
Consulting or Advisory Role - Vittoria Biotherapeutics
Research Funding - Corvus Pharmaceuticals; Genentech
 
Deepa Jagadeesh
Consulting or Advisory Role - AFM; Daiichi Sankyo/Lilly; Genmab
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Debiopharm Group (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); MEI Pharma (Inst); Merck (Inst); Regeneron (Inst); Rhizen Pharmaceuticals (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Eric Mou
Consulting or Advisory Role - Abbvie
 
Andy Chen
Consulting or Advisory Role - Elsevier
Research Funding - Atara Biotherapeutics; Bristol-Myers Squibb; Fate Therapeutics; Kite, a Gilead Company; Novartis
 
Malcolm Brenner
Stock and Other Ownership Interests - Abintus Bio; Allogene Therapeutics; Allovir; Bellicum Pharmaceuticals; Bluebird Bio; Brooklyn ImmunoTherapeutics; Marker Therapeutics; Memgen; poseida therapeutics; Tessa Therapeutics; TScan Therapeutics; Turnstone Bio; Walking Fish Therapeutics
Honoraria - Merck (I)
Consulting or Advisory Role - Abintus Bio; Adaptimmune; Alimera Sciences; AstraZeneca; Athenex; Bellicum Pharmaceuticals; Bluebird Bio; Cell Medica (I); Coya; Formula Pharmaceuticals; Marker Therapeutics; Memgen; NantWorks; Onkimmune; poseida therapeutics; Tessa Therapeutics; torque; TScan Therapeutics; Turnstone Bio; Turnstone Bio; Walking Fish Therapeutics
Research Funding - Cell Medica (I)
Patents, Royalties, Other Intellectual Property - Not applicable because its not related
Travel, Accommodations, Expenses - Bluebird Bio; Merck (I); Tessa Therapeutics; Torque
 
Helen Heslop
Stock and Other Ownership Interests - Allovir; Coregen; Fresh Wind Biotechnologies; March Biosciences; Marker Therapeutics
Consulting or Advisory Role - GlaxoSmithKline; Kiadis Pharma; Marker Therapeutics; Mesoblast; Takara Bio; Tessa Therapeutics
Research Funding - Cell Medica (Inst); Tessa Therapeutics (Inst)
 
Maksim Mamonkin
Stock and Other Ownership Interests - March Biosciences
Honoraria - Fate Therapeutics; Galapagos NV
Consulting or Advisory Role - Curie Bio; Galapagos NV; Laverock Pathology; March Biosciences; NKILT Therapeutics
Research Funding - Fate Therapeutics; March Biosciences
Patents, Royalties, Other Intellectual Property - Allogene Therapeutics; Beam Therapeutics; Fate Therapeutics; March Biosciences
Travel, Accommodations, Expenses - Fate Therapeutics; Galapagos NV
 
Sarah Hein
Employment - March Biosciences
Leadership - March Biosciences
Stock and Other Ownership Interests - March Biosciences
 
Federica Giordano
Employment - March Biosciences
Leadership - March Biosciences
 
Alice Bexon
Employment - Bexon Clinical Consulting
Leadership - March Biosciences; Sapience Therapeutics; Vyriad
Stock and Other Ownership Interests - AI Proteins, Inc; Sapience Therapeutics; Vyriad
Consulting or Advisory Role - March Biosciences; RS Oncology; Sapience Therapeutics; Vyriad
Patents, Royalties, Other Intellectual Property - Patent for AST-008 use in combination with checkpoint inhibitors; Patent for methods of treating cancer with combination therapy (Merck KGaA/PFizer/Vyriad); Patents for Sapience know-how relative to ST101
Travel, Accommodations, Expenses - RS Oncology; Sapience Therapeutics; Vyriad
 
LaQuisa Hill
Consulting or Advisory Role - March Biosciences
Speakers' Bureau - Kite/Gilead